STOCK TITAN

Gamida Cell Ltd - GMDA STOCK NEWS

Welcome to our dedicated news page for Gamida Cell (Ticker: GMDA), a resource for investors and traders seeking the latest updates and insights on Gamida Cell.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gamida Cell's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gamida Cell's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.22%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.41%
Tags
conferences
Gamida Cell Ltd

Nasdaq:GMDA

GMDA Rankings

GMDA Stock Data

7.85M
120.38M
11.58%
26.49%
7.53%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Jerusalem

About GMDA

gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.